Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?

Ziming Li¹, Shun Lu²

Affiliations

¹ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
² Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. Electronic address: shunlu@sjtu.edu.cn.

PMID: 37816330
DOI: 10.1016/j.ccell.2023.09.009

Free article

Comment

Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?

Ziming Li et al. Cancer Cell. 2023.

Free article

. 2023 Oct 9;41(10):1699-1701.

doi: 10.1016/j.ccell.2023.09.009.

Authors

Ziming Li¹, Shun Lu²

Affiliations

¹ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
² Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. Electronic address: shunlu@sjtu.edu.cn.

PMID: 37816330
DOI: 10.1016/j.ccell.2023.09.009

Abstract

In this issue of Cancer Cell, Chen et al. and Pan et al. employ personalized, tumor-informed technology to detect minimal residual disease in non-small-cell lung cancer and demonstrate the clinical promise of integrating liquid biopsy techniques to improve the assessment of cancer progression and metastasis risk.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.L. received research support from AstraZeneca, Hutchison, BMS, Heng Rui, Beigene and Roche, Hansoh, and Lilly Suzhou Pharmaceutical; received speaker fees from AstraZeneca, Roche, Hansoh, and Heng Rui Therapeutics; and served as an advisor and consultant of AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Zai Lab, GenomiCare, Yuhan Corporation, Menarini, InventisBio, and Roche. Ziming Li has none to declare.

Comment on

Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, Wu S, Qiu F, Peng D, Zhu X, Chuai S, Beck S, Kanu N, Carbone D, Zhang Z, Wang J. Chen K, et al. Cancer Cell. 2023 Oct 9;41(10):1749-1762.e6. doi: 10.1016/j.ccell.2023.08.010. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683638
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
Pan Y, Zhang JT, Gao X, Chen ZY, Yan B, Tan PX, Yang XR, Gao W, Gong Y, Tian Z, Liu SM, Lin H, Sun H, Huang J, Liu SY, Yan HH, Dong S, Xu CR, Chen HJ, Wang Z, Li P, Guan Y, Wang BC, Yang JJ, Tu HY, Yang XN, Zhong WZ, Xia X, Yi X, Zhou Q, Wu YL. Pan Y, et al. Cancer Cell. 2023 Oct 9;41(10):1763-1773.e4. doi: 10.1016/j.ccell.2023.09.007. Cancer Cell. 2023. PMID: 37816331

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?

Affiliations

Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical